Age-related macular degeneration and changes in the extracellular matrix

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1003-1016

  Nita, Małgorzata ^a   Strzałka Mrozik, Barbara ^b   Grzybowski, Andrzej ^c,d   Mazurek, Urszula ^b   Romaniuk, Wanda ^b  

^a Domestic and Specialized Medicine Centre 'Dilmed'   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c Poznan City Hospital   (Poland)

^d UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

AMD; Bruch's membrane; Collagen; Elastin; Extracellular matrix; Metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

COLLAGEN; COLLAGEN TYPE 4; COMPLEMENT MEMBRANE ATTACK COMPLEX; DOCOSAHEXAENOIC ACID; ELASTIN; ENTACTIN; FIBULIN; HEPARAN SULFATE; HYPOXIA INDUCIBLE FACTOR 1; LAMININ; MATRIX METALLOPROTEINASE; SERINE PROTEINASE OMI; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

BRUCH MEMBRANE; EXTRACELLULAR MATRIX; GEOGRAPHIC ATROPHY; HUMAN; PATHOGENESIS; PIGMENT EPITHELIUM; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; ENZYMOLOGY; MACULAR DEGENERATION; METABOLISM; PATHOLOGY; WET MACULAR DEGENERATION;

EXTRACELLULAR MATRIX; HUMANS; MACULAR DEGENERATION; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES; WET MACULAR DEGENERATION;

EID: 84902577141     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889887     Document Type: Review

References (204)

1. Chang C, Werb Z: The many faces of metalloproteinases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol, 2001; 11: 37-43
2. Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res, 2006; 69: 562-73
3. Nagase H, Woessner JF: Matrix Metalloproteinases. J Biol Chem, 1999;274(31): 21491-94
4. Steen B, Sejersen S, Berglin L et al: Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci, 1998; 39: 2194-200
5. Visse R, Nagase H: Matrix Metaloproteinases and tissue inhibitors of metaloproteinases. Circ Res, 2003; 92: 827-39
6. Wright JK, Cawston TE, Hazleman BL: Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta, 1991; 1094: 207-10
7. Liotta L, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991; 64: 327-36
8. Nguyen M, Arkell J, Jackson CJ: Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol, 2001; 33: 960-70
9. Kortvely E, Hauck SM, Duetach G et al: ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest Ophtalmol Vis Sci, 2010; 51(1): 79-89
10. Jones SE, Jomary C, Neal MJ: Expression of TIMP3 mRNA is elevated in retinas affected by simplex retinitis pigmentosa. Feder Euro Bioch Soc Letters, 1994; 352: 171-74
11. Yeow KM, Kishnani NS, Hutton M et al: Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinaseinhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol, 2002; 21: 75-88
12. De Jong PT: Age-related macular degeneration. N Engl J Med, 2006; 355: 1474-85
13. Marin-Castaño ME, Striker GE, Alcazar O et al: Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci, 2006; 47: 4098-112
14. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol, 2004; 122(4): 598-614
15. Elner SG, Elner VM, Kindzelskii AL et al: Human RPE cell lysis of extracellular matrix: functional urokinase plasminogen activator receptor (uPAR), collagenase and elastase. Exp Eye Res, 2003; 76: 585-95
16. Sebag J, Hageman GS. Interfaces. Eur J Ophthalmol, 2000; 10(1): 1-3
17. Sivaprasad S, Bailey TA, Chong VNH: Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease?. Clin Exp Ophthalmol, 2005; 33: 518-23
18. Hammer TH, Schlotzer-Schrehardt U, Naumann G: Unilateral or asymetric pseudoexfoliation syndrome? An ultrastructural study. Arch Ophthalmol, 2001; 119(7): 1023-31
19. Ritch R, Schlotzer-Schrehardt U: Exfoliation Syndrom. Survey of Ophthalmol, 2001; 45(4): 265-316
20. Schlotzer-Schrehardt U, von der Mark K, Sakai LY, Naumann GO: Increased extracallular deposition of fibrillin-containing fibrils in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci, 1997; 38: 970-84
21. Ishibashi T, Araki H, Sugai S et al: Detection of proteoglycans in human posterior capsule opacification. Ophthalmic Res, 1995; 27: 208-13
22. Ishibashi T, Hatae T, Inomata H: Collagen types in human posterior capsule opacification. J Cataract Refract Surg, 1994; 20: 643-46
23. Nishi O, Nishi K, Fujiwara T et al: Effects of the cytokines on the proliferation of and collagen synthesis by human cataract lens epithelial cells. Br J Ophthalmol, 1996; 80: 63-68
24. Saika S, Kawashima Y, Miyamoto T et al: Immunolocalization of prolyl 4 hydroxylase subunits, a-smooth muscle actin, and extracellular matrix components in human lens capsules with lens implants. Exp Eye Res, 1998a; 66: 283-94
25. Saika S, Kawashima Y, Miyamoto T et al: Immunohistochemical identification of proteoglycan types in fibrotic human capsules with intraocular lens implants. Jpn J Ophthalmol, 1998b; 42: 368-72
26. Chronopoulos A, Trudeau K, Roy S et al: High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr Eye Res, 2011; 36(8): 747-53
27. Comer GM, Ciulla TA: Pharmacotherapy for diabetic retinopathy Curr Opin Ophthalmol, 2004; 15(6): 508-18
28. Hosoda Y, Okada M, Matsumura M et al: Epiretinal membrane of proliferative diabetic retinopathy: an immunohistochemical study. Ophthalmic Res, 1993; 25(5): 289-94
29. Fine SL, Berger JW, Maguire MG, Ho AC: Age-related macular degeneration. N Engl J Med, 2000; 342: 483-92
30. Klein R, Peto T, Bird A, Vannewkirk MR: The epidemiology of age-related macular degeneration. Am J Ophthalmol, 2004; 137: 486-95
31. Evans JR: Risk factors for age-related macular degeneration. Prog Retin Eye Res, 2001; 20: 227-53
32. McCarty CA, Mukesh BN, Fu CL et al: Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol, 2001; 119: 1455-62
33. McConnell V, Silvestri G: Age-related macular degeneration. Ulster Med J, 2005; 74: 82-92
34. Smith W, Assink J, Klein R et al: Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology, 2001; 108: 697-704
35. Elliot SJ, Catanuto P, Espinosa-Heidmann DG et al: Estrogen receptor b protects against in vivo injury in RPE cells. Exp Eye Res, 2010; 90: 10-16
36. Alcazar O, Hawkridge AM, Collier TS et al: Proteomics Characterization of cell membrane blebs in human retinal pigment epithelium cells. Mol Cell Proteomics, 2009; 8(10): 2201-11
37. Friedman E: The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol, 2000; 130: 658-63
38. Hyman L, Schachat AP, He Q, Leske MC: Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol, 2000; 118: 351-58
39. Jonas JB, Hayreh SS, Martus P: Influence of arterial hypertension and diet-induced atherosclerosis on macular drusen. Graefes Arch Clin Exp Ophthalmol, 2003; 241(2): 125-34
40. Klein R, Klein BE, Tomany SC, Cruickshanks KJ: The association of cardiovascular disease with the long-term incidence of age-related maculopathy. Ophthalmology, 2003; 110: 1273-80
41. Praddaude F, Cousins SW, Pêcher C, Marin-Castano ME: Angiotensin IIinduced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium. Exp Eye Res, 2009; 89: 109-18
42. Snow KK, Seddon JM: Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol, 1999; 6: 125-43
43. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A: Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res, 1989; 58: 3743-50
44. George SJ: Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis Curr Opin Lipidol, 1998; 9: 413-23
45. Marin-Castaño ME, Csaky KG, Cousins SW: Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. Invest Ophthalmol Vis Sci, 2005; 46: 3331-40
46. Pauleikhoff D, Barondes MJ, Minassian D et al: Drusen as risk factors in age-related macular disease. Am J Ophthalmol, 1990; 109: 38-43
47. Sheridan CM, Hiscott P, Grierson I: The role of glycoproteins and integrins in human RPE-induced collagen matrix contraction. Exp Eye Res, 2000; 71: S119
48. Vinding T: Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration An epidemiological study of 1000 aged individuals. Acta Ophthalmol (Copenh), 1990; 68: 410-14
49. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M: Ocular neovascularization. Basic mechanisms and therapeutic advances. Surv Ophthalmol, 2007; 52: 3-19
50. Witmer AN, Vrensen GF, van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res, 2003; 22(1): 1-29
51. Agtmael TV, Bruckner-Tuderman L: Basement membranes and human disease. Cell Tissue Res, 2010; 339: 167-88
52. Bai X, Dilworth DJ, Weng Yi-C et al: Developmental distribution of collagen IV isoforms and relevance to ocular diseases. Matrix Biology, 2009; 28: 194-201
53. Schittny JC, Yurchenco PD: Basement membranes: molecular organization and function in development and disease. Curr Opin Cell Biol, 1989; 1(5): 983-88
54. Alcazar O, Cousins SW, Striker GE, Marin-Castano ME: (Pro)renin receptor is expressed in human retinal pigment epithelium and participates in extracellular matrix remodeling. Exp Eye Res, 2009; 89: 638-47
55. Nagasse H: Activation mechanism of matrix metalloproteinases. Biol Chem, 1997; 378: 151-60
56. Ellerbroek SM, Stack SM: Membrane associated matrix metalloproteinases in metastasis Bioessays, 1999; 21: 940-49
57. Chen L, Miyamura N, Ninomiya Y, Handa JT: Distribution of the collagen IVisoforms in human Bruch's membrane. Br J Ophthalmol, 2003; 87(2): 212-15
58. Das A, Frank RN, Zhang NL, Turczyn TJ: Ultrastructural localization of extracellular matrix components in human retinal vessels and Bruch's membrane. Arch Ophthalmol, 1990; 108(3): 421-29
59. Erickson AC, Couchman JR: Still more complexity in mammalian basement membranes. J Histochem Cytochem, 2000; 48(10): 1291-306
60. Gould DB, Marchant JK, Savinova OV et al: Col4a1 mutation causes endoplasmic reticulum stress and genetically modifiable ocular dysgenesis. Hum Mol Genet, 2007; 16(7): 798-807
61. Favor J, Gloeckner CJ, Janik D et al: Type IV procollagen missense mutations associated with defects of the eye, vascular stability, the brain, kidney function and embryonic or postnatal viability in the mouse, Mus musculus: an extension of the Col4a1 allelic series and the identification of the first two Col4a2 mutant alleles. Genetics, 2007; 175: 725-36
62. Parkin JD, San Antonio JD, Pedchenko V et al: Mapping structural landmarks, ligand binding sites, and missense mutations to the Collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes. Hum Mutation, 2011; 32(2): 127-43
63. Khoshnoodi J, Pedchenko V, Hudson BG: Mammalian collagen IV. Microsc Res Tech, 2008; 71: 357-70
64. Poschl E, Schlotzer-Schrehardt U, Brachvogel B et al: Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development, 2004; 131: 1619-28
65. Ekblom M, Falk M, Salmivirta K et al: Laminin isoforms and epithelial development. Ann NY Acad Sci, 1998; 23(857): 194-211
66. Marshall GE, Konstas AG, Reid GG et al: Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula. Br J Ophthalmol, 1992; 76: 607-14
67. Ortega N, Werb Z: New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci, 2002; 115: 4201-14
68. Volonghi I, Pezzini A, del Zotto E et al: Role of COL4A1 in basement-membrane integrity and cerebral small-vessel disease. The COL4A1 Stroke Syndrome. Curr Med Chem, 2010; 17(13): 1317-24
69. Miner JH: Laminins and their roles in mammals. Microsc Res Tech, 2008; 71: 349-56
70. Smyth N, Vatansever HS, Murray P et al: Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. J Cell Biol, 1999; 144: 151-60
71. McKee KK, Harrison D, Capizzi S, Yurchenco PD: Role of laminin terminal globular domains in basement membrane assembly. J Biol Chem, 2007; 282: 21437-47
72. Bader BL, Smyth N, Nedbal S et al: Compound genetic ablation of nidogen 1 and 2 causes basement membrane defects and perinatal lethality in mice. Mol Cell Biol, 2005; 25: 6846-56
73. Kimura N, Toyoshima T, Kojima T, Shimane M: Entactin-2: a new member of basement membrane proteins with high homology to entactin/ nidogen. Exp Cell Res, 1998; 241: 36-45
74. Kohfeldt E, Sasaki T, Gohring W, Timpl R: Nidogen-2: a new basement membrane protein with diverse binding properties. J Mol Biol, 1998; 282: 99-109
75. Chakravarti S, Tam MF, Chung AE: The basement membrane glycoprotein entactin promotes cell attachment and binds calcium ions. J Biol Chem, 1990; 265: 10597-603
76. Gumbiner B: Cell adhesion: The molecular basis of tissue architecture and morphogenesis. Cell, 1996; 84: 345-57
77. Gohring W, Sasaki T, Heldin CH, Timpl R: Mapping of thebinding of platelet derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur J Biochem, 1998; 255: 60-66
78. Hewitt AT, Nakazawa K, Newsome DA: Analysis of newly synthesized Bruch's membrane proteoglycans. Invest Ophthalmol Vis Sci, 1989; 30(3): 478-86
79. Iozzo RV: Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem, 1998; 67: 609-52
80. Miettinen A, Stow JL, Mentone S, Farquhar MG: Antibodies to basement membrane heparan sulfate proteoglycans bind to thelaminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening. J Exp Med, 1986; 163: 1064-84
81. Guymer R, Luthert P, Bird A: Changes in Bruch's membrane and related structures with age. Prog Retin Eye Res, 1999; 18: 59-90
82. Gautieri A, Uzel S, Vesentini S et al: Molecular and mesoscale mechanisms of osteogenesis imperfecta disease in collagen fibrils. Biophysical J, 2009; 97: 857-65
83. Marini JC, Forlino A, Cabral WA et al: Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat, 2007; 28: 209-21
84. Sweeney SM, Orgel JP, Fertala A et al: Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. J Biol Chem, 2008; 283: 21187-97
85. Imai H, Honda S, Kondo N et al: The upregulation of angiogenic gene expression in cultured retinal pigment epithelial cells grown on type I collagen. Curr Eye Res, 2007; 32: 903-10
86. Roberts JM, Forrester JV: Factors affecting the migration and growth of endothelial cells from icrovessels of bovine retina. Exp Eye Res, 1990; 50: 165-72
87. Chong NHV, Keonin J, Luthert PJ et al: Decreased Thickness and Integrity of the Macular Elastic Layer of Bruch's Membrane Correspond to the Distribution of Lesions Associated with Age-Related Macular Degeneration. Am J Pathol, 2005; 166(1): 240-51
88. Kondo N, Honda S, Ishibashi K et al: Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci, 2008; 49: 1101-5
89. Nackman G, Karkowski F, Halpern V et al: Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Surgery, 1997; 122: 39-44
90. Fisher SA, Rivera A, Fritsche LG et al: Case-control genetic association study of fibulin-6 (FBLN6 or HMCN1) variants in age-related macular degeneration (AMD). Hum Mutat, 2007; 28: 406-13
91. Schultz DW, Klein ML, Humpert AJ et al: Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Hum Mol Genet, 2003; 12: 3315-23
92. Zhang Y, Marmorstein LY: Focus on molecules: Fibulin-3 (EFEMP1). Exp Eye Res, 2010; 90: 374-75
93. Fu L, Garland D, Yang Z et al: The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. Hum Mol Genet, 2007; 16: 3411-22
94. Marmorstein LY, Munier FL, Arsenijevic Y et al: Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc Natl Acad Sci USA, 2002; 99: 13067-72
95. Stone EM, Braun TA, Russell SR et al: Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med, 2004; 351: 346-53
96. Stone EM, Lotery AJ, Munier FL et al: A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet, 1999; 22: 199-202
97. Anderson DH, Guerin CJ, Matsumoto B, Pfeffer BA: Identification and localization of a beta1 receptor from the integrin family in mammalian retinal pigment epithelial cells. Invest Ophthalmol Vis Sci, 1990; 31: 81-93
98. Ghosh S, Brown R, Jones JC et al: Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha 3 beta 1 integrin in oral keratinocytes. J Biol Chem, 2000; 275: 23869-76
99. Sheridan CM, Williams R, Grierson I: Basement membranes and artificial substratesin cell transplantation. Graefe's Arch Clin Exp Ophthalmol, 2004; 242: 68-75
100. Timpl R, Brown JC: Aassembly of basement membranes. Bio Essays, 1996; 18: 123-32
101. White DJ, Puranen S, Johnson MS, Heino J: The collagen receptor subfamily of the integrins. Int J Biochem Cell Biol, 2004; 36: 1405-10
102. Wu C: Roles of integrins in fibronectin matrix assembly. Histol Histopathol, 1997; 12: 233-40
103. Schwarzbauer J: Basement membrane: Putting up the barriers. Current Biology, 1999; 9: R242-44
104. Tummalapalli C, Tyagi S: Responses of vascular smooth muscle cell to extracellular matrix degradation. J Cell Biochem, 1999; 75: 515-27
105. Kwak N, Okamoto N, Wood J, Campochiaro P: VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci, 2000; 41: 3158-64
106. Schwesinger C, Yee C, Rohan R: Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol, 2001; 158: 1161-72
107. Spilsbury K, Garrett K, Shen W et al: Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol, 2000; 157: 135-44
108. Banda MJ, Clark EJ, Werb Z: Selective proteolysis of immunoglobulins by mouse macrophage elastase. J Exp Med, 1983; 157: 1184-96
109. Banda JJ, Clark EJ, Werb Z: Limited proteolysis by macrophage elastase inactivates human a-1-proteinase inhibitor. J Exp Med, 1980; 152: 1563-70
110. Espinosa-Heidmann DG, Suner IJ, Catanuto P et al: Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci, 2006; 47(2): 729-38
111. Lee SH, Goswami, S Grudo A et al: Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med, 2007; 13: 567-69
112. Chau KY, Sivaprasad S, Patel N et al: Plasma levels of matrix metalloproteinase-2 and-9 (MMP-2 and MMP-9) in age-related macular degeneration. Eye, 2007; 21: 1511-15
113. Zhuge Y, Xu J: Rac1 mediates type I collagen-dependent MMP-2 activation role in cell invasion across collagen barrier. J Biol Chem, 2001; 276: 16248-56
114. Leu ST, Batni S, Radeke MJ et al: Drusen are cold spots for proteolysis: expression of matrix metalloproteinases and their tissue inhibitor proteins in age-related macular degeneration. Exp Eye Res, 2002; 74: 141-54
115. Alcazar O: MMP-14 and TIMP-2 overexpression protects against hydroquinone-induced oxidant injury in RPE: implications for extracellular matrix turnover. Invest Ophthalmol Vis Sci, 2007; 48: 5662-70
116. Alexander JP, Bradley JMB, Gabourel JD, Acott TS: Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci, 1990; 31: 2520-28
117. Dhaliwal BS, Steinbrecher UP: Scavenger receptors and oxidized low density lipoproteins. Clin Chim Acta, 1999; 286: 191-205
118. Baker AH, Zaltsman AB, George SJ, Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro TIMP-3 promotes apoptosis. J Clin Invest, 1998; 101: 1478-87
119. Stohr H, Roomp K, Felbor U, Weber BHF: Genomic organization of the human Tissue Inhibitor of Metalloproteinases-3 (TIMP3). Genome Res, 1995; 5: 483-87
120. Kamei M, Hollyfield JG: TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci, 1999; 40: 2367-75
121. Moses MA, Langer R: A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem, 1991; 47; 230-35
122. Newsome DA, Hewitt AT, Huh W et al: Detection of specific extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body. Am J Ophthalmol, 1987; 104: 373-81
123. Karwatowski WS, Jeffries TE, Duance VC et al: Preparation of Bruch's membrane and analysis of the age-related changes in the structural collagens. Br J Ophthalmol, 1995; 79: 944-52
124. Yamamoto T, Yamashita H: Scanning electron microscopic observation of Bruch's membrane with the osmium tetroxide treatment. Br J Ophthalmol, 1989; 73: 162-67
125. Spraul CW, Lang GE, Grossniklaus HE, Lang GK: Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with agerelated macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol, 1999; 44(Suppl.1): S10-32
126. Green WR: Histopathology of age-related macular degeneration. Mol Vis, 1999; 5: 27
127. van der Schaft TL, Mooy CM, de Bruijn WC et al: Immunohistochemical light and electron microscopy of basal laminar deposit Graefes Arch Clin Exp Ophthalmol, 1994; 232: 40-46
128. van der Schaft TL, Mooy CM, de Bruijn WC et al: Histologic features of the early stages of age-related macular degeneration: A statistical analysis. Ophthalmology, 1992; 99: 278-86
129. Pauleikhoff D, Harper CA, Marshall J, Bird AC: Aging changes in Bruch's membrane: a histochemical and morphologic study. Ophthalmology, 1990b; 97: 171-78
130. Sheraidah G, Steinmetz R, Maguire J et al: Correlation between lipids extracted from Bruch's membrane and age. Ophthalmology, 1993; 100: 47-51
131. Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D: Characterization of peroxidized lipids in Bruch's membrane. Retina, 1999; 19: 141-47
132. Booji JC, Baas AC, Beisekeeva J et al: The dynamic nature of Bruch's membrane. Prog Retin Eye Res, 2010; 29: 1-18
133. Chen SJ, Cheng CY, Lee AF et al: Pulsatile ocular blood flow in asymmetric exudative age-related macular degeneration. Br J Ophthalmol, 2001; 85; 1411-15
134. McLeod DS, Taomoto M, Otsuji T et al: Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration Invest Ophthalmol Vis Sci, 2002; 43: 1986-93
135. McLeod DS, Lutty GA: High-resolution histologic analysis of the human choroidal vasculature. Invest Ophthalmol Vis Sci, 1994; 35: 3799-811
136. Nasir M, Sugino I, Zarbin MA: Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration. Br J Ophthalmol, 1997; 81: 481-89
137. Curcio CA, Presley JB, Millican CL, Medeiros NE: Basal deposits and drusen in eyes with age-related maculopathy: evidence for solid lipid particles. Exp Eye Res, 2005; 80: 761-75
138. Curcio CA, Millican CL: Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol, 1999; 117: 329-39
139. Sarks SH, Cherepanoff S, Killingsworth M, Sarks J: Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthal Vis Sci, 2007; 48: 968-77
140. Green WR, Enger C: Age-related macular degeneration histopathologic studies. Ophthalmology, 1993; 100: 1519-35
141. Hillenkamp J, Hussain AA, Jackson TL et al: The influence of path length and matrix components on ageing characteristics of transport between the choroid and the outer retina. Invest Ophthalmol Vis Sci, 2004; 45: 1493-98
142. Hussain AA, Rowe L, Marshall J: Age-related alterations in the diffusional transport of amino acids across the human Bruch's-choroid complex. J Opt Soc Am A Opt Image Sci Vis, 2002; 19(1): 166-72
143. Moore DJ, Clover GM: The effect of age on the macromolecular permeability of human Bruch's membrane. Invest Ophthalmol Vis Sci, 2001; 42: 2970-75
144. Starita C, Hussain AA, Pagliarini S, Marshall J: Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp Eye Res, 1996; 62: 565-72
145. Sparrow JR, Boulton M: RPE lipofuscin and its role in retinal pathobiology Exp Eye Res, 2005; 80(5): 595-606
146. Ng KP, Gugiu B, Renganathan K et al: Retinal pigment epithelium lipofuscin proteomics. Mol Cell Proteomics, 2008; 7(7): 1397-405
147. Warburton S, Southwick K, Hardman RM et al: Examining the proteins of functional retinal lipofuscin using proteomic analysis as a guide for understanding its origin. Mol Vis, 2005; 15(11): 1122-34
148. Reale E, Groos S, Eckardt U et al: New components of 'basal laminar deposits' in age-related macular degeneration. Cells Tissues Organs, 2009; 190: 170-81
149. Crabb JW, Miyagi M, Gu X et al: Drusen proteome anlysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA, 2002; 99(23): 14682-87
150. Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP: Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br J Ophthalmol, 1999; 83(3): 358-68
151. Umeda S, Suzuki MT, Okamoto H et al: Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different of macular degeneration in cynomolgus monkey (Macaca fascicularis). FASEB J, 2005; 19(12): 1683-85
152. Ferris FL, Davis MD, Clemons TE et al: A simplified severity scale for age-related macular degeneration: AREDS Report No 18. Arch Ophthalmol, 2005; 123: 1570-74
153. Wang JJ, Foran S, Smith W, Mitchell P: Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: The Blue Mountains Eye Study Cohort. Arch Ophthalmol, 2003; 121: 658-63
154. Bressler NM, Munoz B, Maguire MG et al: Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities Waterman study. Arch Ophthalmol, 1995; 113: 301-8
155. Bressler SB, Maguire MG, Bressler NM, Fine SL: Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol, 1990; 108: 1442-47
156. Klein R, Klein BE, Jensen SC, Meuer SM: The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology, 1997; 104: 7-21
157. Sarraf D, Gin T, Yu F et al: Long-term drusen study. Retina, 1999; 19: 513-19
158. rd ed. St Louis, Mosby, 2001: 1064-99
159. Hageman GS, Mullins RF, Clark WG et al: Drusen share molecular constituents common to atherosclerotic, elastotic and amyloid deposits. Invest Ophthalmol Vis Sci, 1995; 36: 432
160. Mullins RF, Russel SR, Anderson DH, Hageman GS: Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis and dense deposit disease. FASEB J, 2000; 14(7): 835-46
161. Mullins RF, Johnson LV, Anderson DH, Hageman GS: Characterization of drusen-associated glycoconjugates. Ophthalmology, 1997; 104(2): 288-94
162. Pauleikhoff D, Sheraidah G, Marshall J et al: Biochemical and histochemical analysis of age related lipid deposits in Bruch's membrane. Ophthalmology, 1994; 91: 730-34
163. Anderson DH, Mullins RF, Hageman GS, Johnson LV: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol, 2002; 134: 411-31
164. Augustin AJ, Kirchhof J: Inflammation and pathogenesis of age-related macular degeneration. Expert Opin Ther Targets, 2009; 13(6): 641-51
165. Donoso LA, Kim D, Frost A et al: The role of inflammation in the pathogenesis age-related macular degeneration. Surv Ophthalmol, 2006; 51(2): 137-52
166. Hageman GS, Luther PJ, Chong VNH et al: An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPEBruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res, 2001; 20(6): 705-32
167. Johnson LV, Ozaki S, Staples MK et al: A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res, 2000; 70: 441-49
168. Kijlstra A, La Heij E, Hendrikse F: Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm, 2005; 13(1): 3-11
169. Xu H, Chen M, Forrester JV: Para-inflammation in aging retina. Prog Retin Eye Res, 2009; 28(5): 348-68
170. Despriet DD, van Duijn CM, Oostra BA et al: Complement component C3 and risk of age-related macular degeneration. Ophthalmology, 2009; 116(3): 474-80
171. Grossniklaus HE, Jing JX, Wallace TM et al: Macrophages and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis, 2002; 21(8): 119-26
172. Zipfel PF, Heinen S, Józsi M, Skerka C: Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol, 2006; 43: 97-106
173. Gasgue P, Dean YD, McGreal EP et al: Complement components of innate immune system in health and disease in the CNS. Immunopharmacology, 2000; 49: 171-86
174. Rodriguez de Cordoba SR, Esparza-Gordillo J, Goicoechea de Jorge E et al: The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol, 2004; 41: 355-67
175. Zhou J, Kim SR, Westlund BS, Sparrow JR: Complement activation by bisretinoid constituents of RPE lipofuscin. Invest Ophthalmol Vis Sci, 2009;50(3): 1392-99
176. Zhou J, Jang YP, Kim SR, Sparrow JR: Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA, 2006; 103(44): 16182-87
177. Zipfel PF: Complement and immune defense: from innate immunity to human diseases. Immunol Lett, 2009; 22(126): 1-7
178. Edwards A, Ritter R, Abel K et al: Complement factor H polymorphism and age-related macular degeneration. Science, 2005; 308: 421-24
179. Hageman GS, Anderson D, Johnson L et al: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposesindividuals to agerelated macular degeneration. Proc Natl Acad Sci USA, 2005; 102: 7227-32
180. Haines J, Hauser, M Schmidt S et al: Complement factor H variant increases the risk of age-related macular degeneration. Science, 2005; 308: 419-21
181. Klein R, Zeiss C, Chew E et al: Complement factor H polymorphism in agerelated macular degeneration. Science, 2005; 308: 385-89
182. Józsi M, Zipfel PF: Factor H family proteins and human diseases. Trends Immunol, 2008; 29(8): 380-87
183. Gu X, Meer SG, Miyagi M et al: Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem, 2003; 278(43): 42027-35
184. Bazan NG: Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci, 2006; 29(5): 263-71
185. San Giovanni JP, Chew EY: The role of omega-3 long-chain polyunsaturated fatty acid in health and disease of the retina. Prog Retin Eye Res, 2005;24(1): 87-138
186. Stilwell W, Wassal SR: Docosahexaenoic acid: membrane properties of a unique fatty acid Chem Phys Lipids, 2003; 126(1): 1-27
187. Hollyfield JG, Bonilha VL, Rayborn ME et al: Oxydative damage-induced inflammation initiates age-related macular degeneration. Nat Med, 2008;14(2): 194-98
188. Renganathan K, Ebrahem Q, Vasanji A et al: Carboxyethylpropyrrole adducts, age-related macular degeneration and neovascularization. Adv Exp Med Biol, 2008; 613: 261-67
189. Ebrachem Q, Renganathan K, Sears J et al: Carboxyethylpropyrrole oxidative protein modifications stimulate neovascularization: Implifications for age-related macular degeneration. Proc Natl Acad Sci USA, 2006; 103(36): 13480-84
190. Bhutto IA, McLeod DS, Hasegawa T et al: Pigment epithelium derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroids and eyes with age-related macular degeneration. Exp Eye Res, 2006; 82: 99-110
191. De Luca A, De Falco M, Severino A et al: Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem, 2003; 51: 1279-84
192. De Wan A, Liu M, Harman S et al: HTRA1 promoter polymorphism in wet age-related macular degeneration. Science, 2006; 314: 989-92
193. Yang Z, Camp NC, Sun H et al: A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science, 2006; 314: 992-93
194. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1): implications for macular degenerations. J Biol Chem, 2004; 279; 30469-73
195. Klein ML, Schultz DW, Edwards A et al: Age-related macular degeneration: clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol, 1998; 116: 1082-88
196. Rivera A, Fisher SA, Fritsche LG et al: Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet, 2005; 14: 3227-36
197. Wang G, Spencer KM, Court BL et al: Age-related macular degeneration associated ARMS2 is not a mitochondrial but cytosolic protein. Invest Ophthalmol Vis Sci, 2009; 50(7): 3084-90
198. Fritsche LG, Loenhardt T, Janssen A et al: Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet, 2008; 40(7): 892-96
199. Iyengar SK, Song D, Klein BE et al: Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet, 2004; 74: 20-39
200. Andreasen PA, Kjoller L, Christensen L, Duffy MF: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer, 1997; 72: 1-22
201. Bressler NM: Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology, 2009; 116(10 Suppl.): 15-23
202. Cruess AF, Zlateva G, Pleil AM, Wirostko B: Photodynamic therapy with verteporfin in age-related macular degeneration: asystematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol, 2009; 87(2): 118-32
203. Ruiz-Moreno JM, Montero JA: Combined treatment of exudative age-related macular degeneration with photodynamic therapy and intravitreal triamcinolone. Clin Ophthalmol, 2008; 2(1): 71-75
204. Shah GK, Sang DN, Hughes MS: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina, 2009;29(2): 133-48